Real-World study checks T-DM1 safety and effectiveness in chinese breast cancer patients

NCT ID NCT05945927

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Jun 20, 2026 · Updated 37 times

Summary

This study looked at 178 Chinese patients with HER2-positive advanced breast cancer who received the drug T-DM1 after earlier treatments failed. Researchers tracked side effects and how long the drug kept the cancer from getting worse. The goal was to see how well T-DM1 works in real-world settings, not just in controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Affiliated Hospital of Hebei University

Baoding, China
Affiliated Hospital of Nantong University

Nantong, 226001, China
Anhui Province Cancer Hospital

Hefei, 230031, China
Anyang Tumor Hosptial

Anyang, 455000, China
Beijing Hospital

Beijing, 100730, China
Cancer Hospital Affliated to Xinjiang Medical University

Ürümqi, 830011, China
Cancer Hospital Chinese Academy of Medical Sciences Shenzhen Center

Shenzhen, 518127, China
Cancer Hospital Chinese Academy of Medical Sciences.

Beijing, 100021, China
China Medical University (CMU) First Affiliated Hospital

Shenyang, 110001, China
Dongyang People's Hospital

Jinhua, China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University

Xi'an, 710061, China
Fujian Cancer Hospital

Fuzhou, 350014, China
Guangxi Cancer Hospital of Guangxi Medical University

Nanning, 530021, China
Harbin Medical University Cancer Hospital

Harbin, 150081, China
Hubei Cancer Hospital

Wuhan, 430079, China
Jiangmen Central Hospital

Jiangmen, 529030, China
Nanjing Gulou Hospital

Nanjing, China
Ningbo No.2 Hospital

Ningbo, China
Shanxi Provincial Cancer Hospital

Taiyuan, 030013, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, 510120, China
The Affiliated Cancer Hospital of Guizhou Medical University

Guiyang, China
The First Affiliated Hospital Of Shandong First Medical University

Jinan, 250014, China
The Third Hospital of Nanchang

Nanchang, 330009, China
Tianjin Cancer Hospital

Tianjin, China
Union Hospital of Tongji Medical College, Dept. of Cancer Center

Wuhan, 430023, China
Weifang People's Hospital

Weifang, 261041, China
West China Hospital of Sichuan University

Chengdu, 610041, China
Yibin Second People's Hospital

Yibin, China
Zhejiang Cancer Hospital

Zhejiang, 310022, China
the First Hospital of Jilin University

Changchun, 130021, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

trastuzumab emtansine (T-DM1)

What this could lead to

If results are positive, this could confirm that T-DM1 works well and is safe for Chinese patients with advanced HER2-positive breast cancer in everyday care.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations or settings.

Conditions

The condition(s) this trial relates to.

breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER